Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer

Clinics

Volumn 68, Issue 5, 2013, Pages 592-598

  Tiezzi, Daniel Guimarães ^a   Clagnan, Willian Simões ^a   Mouro Mandarano, Larissa Raquel ^a   de Sousa, Christiani Bisinoto ^a   Cosiski Marana, Heitor Ricardo ^a   Tiezzi, Marcelo Guimarães ^b   de Andrade, Jurandyr Moreira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratório de Anatomia Patológica e Citopatologia de Presidente Prudente   (Brazil)

Author keywords

Breast Cancer; Neoadjuvant Chemotherapy; Prognostic Factors

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84878429077     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(05)03     Document Type: Article

References (42)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74, http://dx.doi.org/10.1073/pnas.191367098.
2. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-8, http://dx.doi.org/10. 1038/367645a0.
3. Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401, http://dx.doi.org/10.1038/nature03128.
4. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983-8, http://dx.doi.org/10.1073/pnas. 0530291100.
5. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010 Jan 1;16(1):45-55, http://dx.doi.org/10.1158/1078-0432. CCR-09-1630.
6. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell. 2007;1(5):555-67, http://dx.doi.org/10.1016/j.stem.2007.08. 014.
7. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011;108(19):7950-5, http://dx.doi.org/10.1073/pnas.1102454108.
8. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-73, http://dx.doi.org/10.1038/nrc2620.
9. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-42, http://dx.doi.org/10.1038/nrm1835.
10. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98(18):10356-61, http://dx.doi.org/10.1073/pnas. 171610498.
11. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10(3):295-305, http://dx.doi.org/10.1038/ncb1691.
12. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxiainducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15(6):501-13, http://dx.doi.org/10.1016/j.ccr.2009.03. 018.
13. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012.
14. Semenza GL. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res. 2001;49(5):614-7, http://dx.doi.org/ 10.1203/00006450-200105000-00002.
15. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483-93.
16. Tiezzi DG, Andrade JM, Marana HR, Zola FE, Peria FM. Breast conserving surgery after neoadjuvant therapy for large primary breast cancer. Eur J Surg Oncol. 2008;34(8):863-7.
17. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-85.
18. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15(12):4234-41, http://dx.doi.org/10.1158/1078-0432.CCR-08-1479.
19. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011;104(11):1730-8, http://dx.doi.org/10.1038/bjc.2011.159.
20. Seo YL, Choi CS, Yoon DY, Yun EJ, Lee YJ, Park SJ, et al. Benign breast diseases associated with cyclosporine therapy in renal transplant recipients. Transplantation proceedings. 2005;37(10):4315-9, http://dx. doi.org/10.1016/j.transproceed.2005.10.111.
21. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672-9.
22. Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clinical pharmacokinetics. 2000;39(6):429-43, http://dx. doi.org/10.2165/00003088-200039060-00004.
23. Mollica F, Jain RK, Netti PA. A model for temporal heterogeneities of tumor blood flow. Microvascular research. 2003;65(1):56-60, http://dx. doi.org/10.1016/S0026-2862(02)00012-2.
24. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clinical pharmacokinetics. 1999;36(2):99-114, http://dx.doi.org/10.2165/00003088-199936020-00002.
25. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006;12(15):4562-8, http://dx.doi. org/10.1158/1078-0432.CCR-05-2690.
26. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43(13):1905-17.
27. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer agents in medicinal chemistry. 2008;8(7):790-7, http://dx.doi.org/ 10.2174/187152008785914798.
28. Grizzle WE, Srivastava S, Manne U. The biology of incipient, preinvasive or intraepithelial neoplasia. Cancer Biomark. 2011;9(1-6):21-39.
29. Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19(4):924-30.
30. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20(5):1260-8, http://dx.doi.org/10.1200/JCO.20.5.1260.
31. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409-18.
32. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama. 2002;288(3):321-33.
33. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998;95(14):7987-92, http://dx.doi.org/10.1073/pnas.95.14.7987.
34. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E. Oxidative stress and cell signalling. Curr Med Chem. 2004;11(9):1163-82, http://dx.doi.org/10. 2174/0929867043365323.
35. Achuthan S, Santhoshkumar TR, Prabhakar J, Nair SA, Pillai MR. Druginduced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem. 2011;286(43):37813-29, http://dx. doi.org/10.1074/jbc.M110.200675.
36. Pietras A, Gisselsson D, Ora I, Noguera R, Beckman S, Navarro S, et al. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J Pathol. 2008;214(4):482-8.
37. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8(20).
38. Ferlay J, International Agency for Research on Cancer., International Association of Cancer Registries. CI5VII electronic database of Cancer incidence in five continents, vol. VII. Lyon, France: International Agency for Research on Cancer, 1997.
39. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007;25(19):2671-7, http://dx.doi.org/ 10.1200/JCO.2006.09.0217.
40. Courtillot C, Plu-Bureau G, Binart N, Balleyguier C, Sigal-Zafrani B, Goffin V, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005;10(4):325-35, http://dx.doi.org/10.1007/s10911-006-9006-4.
41. Tamimi RM, Byrne C, Baer HJ, Rosner B, Schnitt SJ, Connolly JL, et al. Benign breast disease, recent alcohol consumption, and risk of breast cancer: a nested case-control study. Breast Cancer Res. 2005;7(4):R555-62, http://dx.doi.org/10.1186/bcr1039.
42. Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C, et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res. 2010;12(6):R94, http://dx.doi.org/10.1186/bcr2773.